Author

Sandra Machlitt‐Northen

Observed name: Sandra Machlitt-Northen

Institution: GlaxoSmithKline Research & Development Limited (United Kingdom)

Observed institutions: Queen Mary University of London, GlaxoSmithKline (United Kingdom), Open Targets, GlaxoSmithKline Research & Development Limited (United Kingdom)

ORCID: 0000-0002-5495-4198

Observed ORCID: 0000-0002-5495-4198

OpenAlex ID: A5008195485

Open Targets Genetics: systematic identification of trait-associated genes using large-scale genetics and functional genomics

2020 · Maya Ghoussaini, Edward Mountjoy, et al. · Nucleic Acids Research · 604

Open Targets Platform: supporting systematic drug–target identification and prioritisation

2020 · David Ochoa, Andrew Hercules, et al. · Nucleic Acids Research · 503

The next-generation Open Targets Platform: reimagined, redesigned, rebuilt

2022 · David Ochoa, Andrew Hercules, et al. · Nucleic Acids Research · 467

Polygenic scores for schizophrenia and major depression are associated with psychosocial risk factors in children: evidence of gene–environment correlation

2022 · Sandra Machlitt‐Northen, Robert Keers, et al. · Journal of Child Psychology and Psychiatry · 23

The Role of Gene-Environment Interaction in Mental Health and Susceptibility to the Development of Psychiatric Disorders

2020 · Elham Assary, John Vincent, et al. · Springer eBooks · 18

Polygenic risk scores for schizophrenia and major depression are associated with socio-economic indicators of adversity in two British community samples

2022 · Sandra Machlitt-Northen, Robert Keers, et al. · Translational Psychiatry · 13

Gene–Environment Correlation over Time: A Longitudinal Analysis of Polygenic Risk Scores for Schizophrenia and Major Depression in Three British Cohorts Studies

2022 · Sandra Machlitt-Northen, Robert Keers, et al. · Genes · 9

Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study

2024 · Dunbar Ivy, Maurice Beghetti, et al. · European Journal of Pediatrics · 5

PROGRESS‐AD: a phase 2 study to evaluate efficacy and safety of GSK4527226 (AL101), an anti‐sortilin monoclonal antibody, in patients with early Alzheimer’s disease

2024 · Sandra Machlitt‐Northen, Azza Abdelkarim, et al. · Alzheimer s & Dementia

Letter to the Editor, regarding Li L, Zhu X, Chen X, Gao J, Ding C, et al. Advances in targeted therapy for pulmonary arterial hypertension in children. Eur J Pediatr. 2022 Dec 17

2023 · Maurice Beghetti, Dunbar Ivy, et al. · European Journal of Pediatrics

Works count: 10

Citation count: 1,642

H-index: 7

I10-index: 6